REDWOOD CITY, Calif. – biotricity has received clearance from the U.S Food and Drug Administration for a key component of its bioflux monitoring device. “Receiving a 510(k) clearance is a significant accomplishment toward our goal of enabling physicians to remotely monitor and diagnose patients with cardiovascular disease and coronary heart disease,” said Waqaas Al-Siddiq, founder and CEO of biotricity. The company develops multiple solutions for a variety of chronic illnesses by designing monitoring devices paired with chronic care management tools. Once cleared for the market, the device will be used by physicians and hospitals in the diagnostic process, then by patients for long-term care management.
You are here: / / biotricity device component receives FDA clearance